Philogen - About the company
Philogen is a public company based in Sovicille (Italy), founded in 1996 by Duccio Neri and Dario Neri. It operates as a Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders. Philogen has raised $69.7M in funding from The Equity Club. The company has 3473 active competitors, including 1203 funded and 812 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma.
Company Details
Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders. It offers bioactive agents such as cytokines and small molecule ligands directly to disease sites exploiting overexpressed antigens in angiogenesis related disorders such as cancer, rheumatoid arthritis, and AMD.
- Website
- www.philogen.com/
- Social
- Email ID
- *****@philogen.it
Key Metrics
Founded Year
1996
Location
Sovicille, Italy
Stage
Public
Total Funding
$69.7M in 3 rounds
Latest Funding Round
Investors
Ranked
42nd among 3473 active competitors
Annual Revenue
€77.7M as on Dec 31, 2024
Employee Count
87 as on Jul 01, 2024
Similar Companies
Exit Details
Public
Legal entities associated with Philogen
Philogen is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Philogen S P A CIN: IT0005373789 , Italy, Active | Jan 01, 1996 | $84M (As on Dec 31, 2024) | - | - |
Philogen's IPO details
Philogen got listed on Mar 03, 2021.
Click here to take a look at Philogen's IPO in detail
Sign up to download Philogen's company profile
Philogen's funding and investors
Philogen has raised a total funding of $69.7M over 3 rounds. Its first funding round was on Nov 01, 2012. Its latest funding round was a PE round on May 13, 2019 for $*****. 1 investor participated in its latest round. Philogen has 5 institutional investors.
Here is the list of recent funding rounds of Philogen:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 13, 2019 | 1710753 | PE | 7165195 | 5283799 | 4798404 | 5907210 |
Jan 01, 2017 | 1411185 | Grant (prize money) | 5090907 | 3094930 | 4630129 | |
Nov 01, 2012 | 5414013 | Grant (prize money) | 1409719 | 2394700 | 9505803 |
Access funding benchmarks and valuations. Sign up today!View details of Philogen's funding rounds and investors
Philogen's founders and board of directors
Founder? Claim ProfileHere are the details of Philogen's key team members:
- Duccio Neri: Co-Founder of Philogen. Contact Info: 1 email address
- Dario Neri: Co-Founder, CEO & CSO of Philogen.
View details of Philogen's Founder profiles and Board Members
Philogen's employee count trend
Philogen has 87 employees as of Jul 24. Here is Philogen's employee count trend over the years:
Uncover Philogen's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Philogen's Competitors and alternates
Top competitors of Philogen include Jazz Pharmaceuticals, Sana Biotechnology and Kite Pharma. Here is the list of Top 10 competitors of Philogen, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 75/100 | |
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 73/100 | |
7th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
8th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
9th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 72/100 | |
10th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
42nd | Developer of antibody based drugs for angiogenesis-related cancer and inflammatory disorders | $69.7M | 68/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Philogen's competitors? Click here to see the top ones
Philogen's Investments and acquisitions
Philogen has made no investments or acquisitions yet.
Reports related to Philogen
Here is the latest report on Philogen's sector:
News related to Philogen
Filter this listMedia has covered Philogen for 1 event in last 1 year, It was about company updates.
•
•
Sun Pharma inks licensing pact with Philogen for cancer medicationDeccan Herald•Oct 01, 2024•Sun Pharma, Philogen
•
EMA validates Philogen and Sun Pharma’s MAA for melanomaPharmaceutical Technology•Jul 05, 2024•Philogen, Sun Pharma
•
•
Sun Pharma partner's skin cancer drug demonstrates efficacy against skin cancerIndiatimes•Oct 16, 2023•Sun Pharma, Philogen
•
•
•
•
Headline of the day, Philogen signs a deal for its cancer drug and goes publicMoneycontrol•May 30, 2023•Philogen, Sun Pharma
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Philogen
Explore our recently published companies
- Nikon - Rhodes based, 1917 founded, Public company
- Sincerely Nude - London based, 2018 founded, Public company
- Shatalindia - India based, Unfunded company
- Perfunova - Daman based, 2005 founded, Unfunded company
- Gizmodo Japan - Shibuya based, 2006 founded, Unfunded company
- Asia Clean Capital - Binh Thanh based, 2010 founded, Seed company
